Kallikrein 13 Antikörper (AA 262-277)

Produktnummer ABIN289487

Produktdetails anti-Kallikrein 13 Antikörper

Target: Kallikrein 13 (KLK13) (Kallikrein-Related Peptidase 13 (KLK13))

Bindungsspezifität: AA 262-277

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Kallikrein 13 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Aufreinigung: Affinity chromatography purified

Immunogen: KLK-L4 antibody was raised in rabbit using AA 262-277 [IRKYETQQQKWLKGPQ] of the human KLK-L4 protein as the immunogen.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB: 1:500-1:1,000
Optimal conditions should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: Lot specific

Buffer: Affinity purified IgG supplied in PBS with 0.02 % NaN3.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handhabung: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.

Details zu Kallikrein 13

Target: Kallikrein 13 (KLK13) (Kallikrein-Related Peptidase 13 (KLK13))

Andere Bezeichnung: KLK-L4 (KLK13 Produkte)

Synonyme: KLK-L4 antikoerper, KLKL4 antikoerper, Egfbp-2 antikoerper, mGk-13 antikoerper, kallikrein related peptidase 13 antikoerper, kallikrein related-peptidase 13 antikoerper, KLK13 antikoerper, Klk13 antikoerper

Hintergrund: Kallikreins are a subgroup of serine proteases and are implicated in carcinogenesis. The novel KLK gene, KLK-L4, is expressed in a variety of tissues including prostate, salivary gland, breast, and testis. Its expression is regulated by steroid hormones in breast cancer cell lines may be involved in the pathogenesis and/or progression of breast cancer.

Pathways: Komplementsystem